secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0000950170-23-066032
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports Phase 2 XEN1101 MDD trial misses primary endpoint but hits secondary measures
--------------------------------------------------------------------------------

- MADRS at week 6: placebo reduction 13.90; XEN1101 20 mg reduction 16.94 (p=0.135), not statistically significant.
- HAM-D17 (p=0.042) and anhedonia SHAPS (p=0.046) secondary endpoints met statistical significance for 20 mg.
- Early onset: MADRS at week 1 showed significance for 20 mg (p=0.047); CGI-I also significant (p=0.004).
- XEN1101 well tolerated; no SAEs in active arms; common TEAEs: dizziness (17.9%), somnolence (10.7%), headache (8.9%).
- Company exploring future MDD development; XEN1101 also in Phase 3 epilepsy with no titration required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023066032/0000950170-23-066032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023066032/xene-20231127.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-066032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer